For US Healthcare Professionals Only

ZAYNICH™ logo

Microbiology of ZAYNICH™

ZAYNICH™ has an extensive Gram-negative spectrum of activity that includes difficult-to-treat and multi-drug resistant pathogens

In vitro activity does not necessarily correlate with clinical efficacy results.

Clinical infection data

  • Escherichia coli
  • Klebsiella pneumoniae
  • Proteus mirabilis
  • Enterobacter cloacae complex
  • Pseudomonas aeruginosa

In vitro

  • Klebsiella oxytoca
  • Morganella morganii
  • Klebsiella variicola
  • Citrobacter braakii
  • Serratia marcescens
  • Providencia rettgeri
  • Citrobacter freundii
  • Citrobacter koseri
  • Klebsiella aerogenes
  • Proteus vulgaris
  • Providencia stuartii

ZAYNICH™ has been shown to maintain in vitro activity against bacteria that deploy a variety of enzymatic and non-enzymatic resistance mechanisms

Resistance mechanismZAYNICH™
ESBL
AmpC overexpression
KPC (Class A)
OXA-48-like (Class D)
MBLs (NDM, VIM, IMP)
Efflux pump overexpression
Porin downregulation (oprD)
Altered PBPs

ESBL, extended-spectrum β-lactamase; KPC, Klebsiella pneumoniae carbapenemase; MBL, metallo-β-lactamase; NDM, New Delhi metallo-β-lactamase; oprD, outer membrane porin D; PBP, penicillin-binding protein; VIM, Verona Integron-encoded metallo-β-lactamase.

References: 1. ZAYNICH (cefepime and zidebactam) US Prescribing Information. Wockhardt Bio AG; 2026 2. Shah P, Neeravi A, Karthik R, et al. Successful use of cefepime/zidebactam in deep-seated infections due to extensively drug-resistant Pseudomonas aeruginosa: a case series. J Glob Antimicrob Resist. 2025;44:464-469. doi:10.1016/j.jgar.2025.07.009 3. Egge SL, Lewis SJ II, Hakki M. Case commentary: successful use of cefepime/zidebactam (WCK 5222) as a salvage therapy for the treatment of disseminated extensively drug-resistant New Delhi metallo-β-lactamase-producing Pseudomonas aeruginosa infection in an adult patient with acute T-cell leukemia. Antimicrob Agents Chemother. 2023;67(8):e0066323. doi:10.1128/aac.00663-23